Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline

NEXT STORY
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
PREV STORY
Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs

author_avatar
NASDAQ Market News

The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer

Cranbury, NJ, May 09, 2017 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical-stage, oncology-focused ...

author_avatar
NASDAQ Market News

Globus Medical Enters International Market with ExcelsiusGPS® Robotic Guidance and Navigation System

author_avatar
NASDAQ Market News